Warning: file_get_contents(http://normativacookie.promo.it/cookiebar/cookiebar.php?l=Previous issues&site=d3d3LmNhbmNlcndvcmxkLm9yZw==) [function.file-get-contents]: failed to open stream: HTTP request failed! HTTP/1.1 400 Bad Request in E:\SITI\CANCERWORLDWEB\2013\inc\header.php on line 85

Previous issues

Issue 40 January - February 2011

Issue 40 January - February 2011

» [Editorial] Our role in moulding the image of cancer » [Cover Story] Klaus Meier: together we can offer the best of both worlds » [e-Grand Round] Management of metastatic pancreatic cancer: current strategies and future directions » [Cutting Edge] Promoting genetic literacy: cancer control in the BRCA era » [Best Cancer Reporter Award] Desperately seeking a bone marrow match » [Masterpiece] Real compassion is about moving things forward » [Impact Factor] Gemcitabine alone or plus cisplatin for biliary tract cancer? » [Impact Factor] Molecular selection for ‘smart' study design in lung cancer » [Newsround] NEWSROUND

Issue 39 November - December 2010

Issue 39 November - December 2010

» [Editorial] Fake drugs pose a threat to Europe's cancer patients » [Cover Story] Sara Faithfull: unleashing the potential of cancer nursing » [e-Grand Round] Cancer of unknown primary: a diagnostic and therapeutic dilemma » [Cutting Edge] Therapeutic cancer vaccines – there's a new kid on the block » [Best Cancer Reporter Award] Shining a light on nanoparticle therapy » [Masterpiece] Steadfast in Sarajevo » [Spotlight on...] The Clinical Trials Directive: can we get it right second time around? » [Impact Factor] 200 mg-m2 melphalan – the gold standard for multiple myeloma

Issue 38 September - October 2010

Issue 38 September - October 2010

» [Editorial] Is it safe, is it tolerable? Why not ask the patients? » [Cover Story] Angelo Di Leo: mapping the geography of breast cancer » [e-Grand Round] Neurological side-effects caused by recently approved chemotherapy drugs » [Cutting Edge] Charged particle therapy » [Best Cancer Reporter Award] Prize for journalist who tackled taboo subject of rationing cancer therapies » [Masterpiece] Putting the person back into personalised therapies: The concerns of a head and neck cancer specialist » [Impact Factor] Neoadjuvant trial design: time for a brave new world? » [Impact Factor] Are macrophages the bad guys in Hodgkin lymphoma? » [Newsround] NEWSROUND » [Patient Voice] Adopting a child after cancer

Issue 37 July - August 2010

Issue 37 July - August 2010

» [Editorial] Turning the World Cancer Declaration into action » [Cover Story] Serigne Magueye Gueye: an agent for change » [e-Grand Round] Pitfalls and uncommon problems in thyroid cancer management » [Cutting Edge] Grapefruit juice and St John's Wort are just the tip of the iceberg » [Masterpiece] Yes we can treat cancer – even in the poorest countries » [Impact Factor] Chemoradiation in head-and-neck cancer — are we any closer? » [Impact Factor] Preoperative biliary drainage – better stents in specialised centres are needed » [Newsround] Newsround » [Patient Voice] When sex lives suffer

Issue 36 May - June 2010

Issue 36 May - June 2010

» [Editorial] When the trial you need is just over the border » [Cover Story] Jaap Verweij: an intelligent approach to drugs » [e-Grand Round] The treatment of gastrointestinal stromal tumours (GIST) » [Cutting Edge] Who's who in the world of personalised cancer treatments? » [Masterpiece] Blazing a trail in a new type of research » [Impact Factor] Trials and tribulations in primary CNS lymphoma » [Impact Factor] Androgen deprivation therapy for prostate cancer: true love or heartbreak? » [Newsround] Newsround » [Systems & Services] Should you respect a dying wish?

Issue 35 March - April 2010

Issue 35 March - April 2010

» [Editorial] Stop excluding male patients » [Cover Story] Alain Fourquet: taking multidisciplinarity one step further » [e-Grand Round] Neutropenia in cancer patients: risk factors and management » [Cutting Edge] MRI for breast cancer: who benefits, who is harmed? » [Masterpiece] From unwanted interference to indispensable partner » [Impact Factor] Future directions in multimodality therapy for NSCLC » [Impact Factor] Sunitinib versus interferon-á in metastatic RCC » [Patient Voice] Spreading the word » [Newsround] Newsround

Issue 34 January - February 2010

Issue 34 January - February 2010

» [Editorial] A Partnership with potential » [Cover Story] Jan GeiĂźler: We, the patients » [e-Grand Round] Indolent prostate cancer and active surveillance » [Cutting Edge] Keyhole surgery » [Best Cancer Reporter Award] Ten years reporting from the front line » [Masterpiece] Specialism: political oncology » [Impact Factor] Adjuvant chemotherapy in older patients with breast cancer » [Impact Factor] PET–CT imaging in non-small-cell lung cancer » [Newsround] Newsround » [Patient Voice] Shall we try for a baby?

Issue 33 November - December 2009

Issue 33 November - December 2009

» [Editorial] Rare cancers in Europe - tackling a common problem » [Cover Story] Vesna Kesic: exporting excellence in women's cancers » [e-Grand Round] Addressing fertility issues in patients with breast cancer » [Best Cancer Reporter Award] The ‘no miracle cure' story » [Masterpiece] The power behind the World Cancer Declaration » [Spotlight on...] Should we expect better from the media? » [Spotlight on...] Addicted to wonder drugs » [Spotlight on...] Mass media's hit or myth approach to cancer » [Impact Factor] GIST adjuvant therapy - some answers and more questions » [Impact Factor] Role of lymphadenectomy in the staging of endometrial cancer » [Newsround] Newsround

Issue 32 September - October 2009

Issue 32 September - October 2009

» [Editorial] Talking the same language » [Cover Story] Eric Van Cutsem: closing in on GI tumours » [e-Grand Round] State-of-the-art and controversies in germ-cell cancer » [Drug Watch] Gotta get that rhythm - Circadian timing systems and cancer » [Best Cancer Reporter Award] Are we educating women to be afraid? UK health reporter questions the value of simplistic screening messages » [Masterpiece] Vested interests are undermining our efforts to beat cancer - The worries of a battle-hardened German oncologist » [Impact Factor] Effect of treatment interruptions in prostate cancer » [Impact Factor] Endocrine-therapy-related symptoms and breast cancer » [Newsround] Newsround » [Patient Voice] A man with a woman's cancer How can we do better for male breast cancer patients?

Issue 31 July - August 2009

Issue 31 July - August 2009

» [Editorial] Prostate cancer screening: a question of common sense » [Cover Story] Michael Gnant: pushing the boundaries » [e-Grand Round] Advanced epithelial ovarian cancer: improvements in first- and second-line treatment » [Drug Watch] Beyond trench warfare American and European researchers in search of a winning strategy » [Masterpiece] Surfing the wave » [Impact Factor] Bortezomib in newly diagnosed multiple myeloma » [Impact Factor] Vaccine trials in melanoma - time for reflection » [Newsround] Newsround » [Systems & Services] EUROCARE 4 delivers its verdict » [Focus] Angiogenesis inhibition: do tumours have a plan B?

Pagina 4 di 7       1 | 2 | 3 | 4 | 5 | 6 | 7